HRTX - Heron gains on deal to expand sales network for pain therapy Zynrelef
2024-01-08 06:45:18 ET
More on Heron Therapeutics
- Heron Therapeutics Gets Back On Track
- Why Heron Therapeutics Is A Compelling Buy Into 2024
- Heron Therapeutics, Inc. (HRTX) Q3 2023 Earnings Call Transcript
- Biggest stock movers today: Boeing, Harpoon Therapeutics, and more
- Heron Therapeutics GAAP EPS of -$0.17 beats by $0.14, revenue of $31.43M misses by $0.4M
For further details see:
Heron gains on deal to expand sales network for pain therapy Zynrelef